文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

平衡溶液与0.9%生理盐水对危重症患者死亡率的影响:BaSICS随机临床试验

Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-08-10
一句话结论在需要液体扩容的危重症患者中,使用平衡溶液对比0.9%生理盐水并未显著降低90天死亡率(26.4% vs 27.2%,aHR 0.97,95%CI 0.90-1.05)。

BaSICS是一项在巴西75个ICU进行的双盲、析因设计随机临床试验,纳入至少1个不良结局风险因素、需要至少1次液体扩容、预期ICU停留超过24小时的危重症患者,1:1随机接受平衡溶液(n=5522)或0.9%生理盐水(n=5530)作为所有静脉液体。两组均未出现非预期治疗相关严重不良事件。结论不支持在需液体扩容的危重症患者中使用该平衡溶液以降低死亡率。

要点

  • 研究纳入标准:ICU入院且至少1个不良结局风险因素、需要至少1次液体扩容、预期ICU停留超过24小时;排除标准原文未提及。
  • 入组时60.6%患者存在低血压或使用血管升压药,44.3%需要机械通气,48.4%为计划手术入院,两组首日液体量中位数均为1.5 L。
  • 两组均未出现非预期治疗相关严重不良事件,原文未报告具体不良事件类型或发生率。

适用人群与场景

  • 纳入:ICU入院患者,至少1个不良结局风险因素,需要至少1次液体扩容,预期ICU停留超过24小时。
  • 场景:巴西75个ICU,ICU内液体治疗阶段。
  • 排除标准:原文未提及。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值;干预为使用平衡溶液或0.9%生理盐水作为所有静脉液体,两组首日液体量中位数1.5 L。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:双盲、析因设计随机临床试验,巴西75个ICU,随机11 052例,10 520例(95.2%)纳入分析,平均年龄61.1岁(SD 17),44.2%女性。
  • 干预:1:1随机接受平衡溶液(n=5522)或0.9%生理盐水(n=5530)作为所有静脉液体;同时随机分配两种输注速度(另文报告)。
  • 不良事件:两组均无非预期治疗相关严重不良事件。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT),双盲、析因设计。
  • 证据等级或推荐强度:原文未提及。
  • 局限:原文未明确列出局限;设计上为多中心(75个ICU)RCT,但仅来自巴西单一国家,计划手术入院占48.4%,可能影响外推性。

对床旁实践的改变

  • 对于需要液体扩容的危重症患者,使用平衡溶液对比0.9%生理盐水并未显著降低90天死亡率,不支持仅以降低死亡率为目的选用该平衡溶液。
  • 适用人群:ICU入院、至少1个不良结局风险因素、需要至少1次液体扩容、预期ICU停留超过24小时的患者。
  • 不适用人群:原文未提及排除人群。
  • 常见陷阱:不能将本研究的阴性结果外推为平衡溶液在所有液体治疗场景均无效;原文未报告肾脏替代治疗、AKI等次要结局数据。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT02875873。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Intravenous fluids are used for almost all intensive care unit (ICU) patients. Clinical and laboratory studies have questioned whether specific fluid types result in improved outcomes, including mortality and acute kidney injury.

OBJECTIVE: To determine the effect of a balanced solution vs saline solution (0.9% sodium chloride) on 90-day survival in critically ill patients.

DESIGN, SETTING, AND PARTICIPANTS: Double-blind, factorial, randomized clinical trial conducted at 75 ICUs in Brazil. Patients who were admitted to the ICU with at least 1 risk factor for worse outcomes, who required at least 1 fluid expansion, and who were expected to remain in the ICU for more than 24 hours were randomized between May 29, 2017, and March 2, 2020; follow-up concluded on October 29, 2020. Patients were randomized to 2 different fluid types (a balanced solution vs saline solution reported in this article) and 2 different infusion rates (reported separately).

INTERVENTIONS: Patients were randomly assigned 1:1 to receive either a balanced solution (n = 5522) or 0.9% saline solution (n = 5530) for all intravenous fluids.

MAIN OUTCOMES AND MEASURES: The primary outcome was 90-day survival.

RESULTS: Among 11 052 patients who were randomized, 10 520 (95.2%) were available for the analysis (mean age, 61.1 [SD, 17] years; 44.2% were women). There was no significant interaction between the 2 interventions (fluid type and infusion speed; P = .98). Planned surgical admissions represented 48.4% of all patients. Of all the patients, 60.6% had hypotension or vasopressor use and 44.3% required mechanical ventilation at enrollment. Patients in both groups received a median of 1.5 L of fluid during the first day after enrollment. By day 90, 1381 of 5230 patients (26.4%) assigned to a balanced solution died vs 1439 of 5290 patients (27.2%) assigned to saline solution (adjusted hazard ratio, 0.97 [95% CI, 0.90-1.05]; P = .47). There were no unexpected treatment-related severe adverse events in either group.

CONCLUSION AND RELEVANCE: Among critically ill patients requiring fluid challenges, use of a balanced solution compared with 0.9% saline solution did not significantly reduce 90-day mortality. The findings do not support the use of this balanced solution.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02875873.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Zampieri FG, Machado FR, Biondi RS, et al. Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial. JAMA. 2021. PMID: 34375394. doi:10.1001/jama.2021.11684

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。